Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research

News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971

Finance Watch: Bitcoin For Biopharma? Agenus Gives BEST A Shot

Wed, 01/30/2019 - 3:01pm

Investors in a February Biotech Electronic Security Token (BEST) offering will be able to put their money behind a single...

      Related Stories 

Generic Advair: Finally Approved, A Long Time Coming

Wed, 01/30/2019 - 1:26pm

Mylan's generic version of GlaxoSmithKline's blockbuster asthma drug was approved by the US FDA Jan. 30. The commercial value of...

      Related Stories 

Lipid-based Advances In Drug Delivery

Wed, 01/30/2019 - 8:28am

Safe and efficient delivery is a fundamental challenge for personalized medicine, gene therapy and genetic medicine. Specialized and unique delivery...

      Related Stories 

Amicus To See If Its Fabry Drug Galafold Can Benefit From Mis-Diagnosed MS

Wed, 01/30/2019 - 7:41am

Rare disease specialist Amicus Therapeutics' lead product Galafold has recently launched with early success and the company's president tells Scrip further momentum...

      Related Stories 

Carry On Cosentyx As Novartis Lines Up More Blockbusters

Wed, 01/30/2019 - 6:41am

The Swiss giant has posted a strong set of results with the company highly confident that its flagship immune drug...

      Related Stories 

AC Immune/Roche Drop Crenezumab After Phase III CREAD Alzheimer's Failure

Wed, 01/30/2019 - 6:31am

Interim top-line data from CREAD 1 and 2 indicate crenezeumab is unlikely to meet its primary endpoints and the studies...

      Related Stories 

ASLAN Cuts Costs, Jobs And Refocuses After Varlitinib Setback

Tue, 01/29/2019 - 7:40pm

Singapore-based company prioritizes resources and cuts jobs following the recent Phase II failure of its lead pipeline asset in first-line...

      Related Stories 

Amgen Explains How Big A Hit It May Take From Biosimilars, Pricing Pressures

Tue, 01/29/2019 - 6:10pm

With Neulasta and Epogen facing competition and potential Sensipar generics launching this year, the company said revenues will fall from...

      Related Stories 

Biogen To Launch Phase III Alzheimer’s Prevention Study

Tue, 01/29/2019 - 4:58pm

The firm announced plans to begin a Phase III study of aducanumab to prevent or delay the onset of Alzheimer’s...

      Related Stories 

Voyager Nabs Neurocrine As Partner In CNS Gene Therapy

Tue, 01/29/2019 - 2:04pm

Voyager signals Phase II study of gene therapy VY-AADC in Parkinson's disease is on track, with no expectations for regulatory...

      Related Stories 

Allergan Thinks It’s Ready To Withstand Restasis Generics

Tue, 01/29/2019 - 1:19pm

Allergan’s Restasis patent cliff is imminent: full-year sales of the dry eye product declined 14% and the firm expects US...

      Related Stories 

Pfizer: Time To Face The Lyrica Pain

Tue, 01/29/2019 - 1:13pm

Pfizer forecast flat US drug prices in 2019 and downplayed large M&A as a way to assuage near-term growth concerns...

      Related Stories 

Novartis’ Entresto Faces Challenge From Natco In India

Tue, 01/29/2019 - 8:25am

Natco has launched a cut-price version of sacubitril/valsartan (Novartis' Entresto) on the Indian market and is also believed to have...

      Related Stories 

Alexion Looks To Broaden Complement Inhibitor Market With Next-Generation Ultomiris

Tue, 01/29/2019 - 7:41am

Positive late-stage clinical results involving Ultomiris in a second potential indication suggest Alexion is on the right track to develop...

      Related Stories 

Asia Executives On The Move: Comings And Goings At BeiGene, Harbour BioMed, TLC, GC Pharma

Mon, 01/28/2019 - 3:57pm

New Year brings a flurry of new executive moves in the life sciences sector in Asia Pacific, including the departure...

      Related Stories